Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in HFpEF and Obesity (SUMMIT)
NCT04847557Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2021
- Primary completion
- Jul 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of tirzepatide in heart failure with preserved ejection fraction (HFpEF), obesity, sponsored by Eli Lilly and Company. Started Apr 2021; status: completed.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesity
Beyond the preview
Go deeper on NCT04847557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847557.